Can climacteric women self-adjust therapeutic estrogen doses using symptoms as markers?

Maturitas

Volumn 28, Issue 3, 1998, Pages 199-203

  Vihtamäki, Tarja ^a   Tuimala, Risto ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Climacteric women; Gynecology; Obstetrics; Premenstrual

Indexed keywords

ESTRADIOL; ESTROGEN; MEGESTROL ACETATE;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SELF ADMINISTRATION; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; SYMPTOMATOLOGY; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SELF ADMINISTRATION;

EID: 0032509843     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00083-2     Document Type: Article

References (18)

1. Meldrum DR Hot flushes. Estrogen replacement therapy: indications and complications. Ann Intern Med. 98:1983;195.
2. Christiansen C, Christiansen MS, Transböl I Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Lancet. 1:1981;459-461.
3. Christiansen C, Riis BJ 17β-Estradiol and continuous norethisterone: a unique treatment of established osteoporosis in elderly women. J Clin Endocrinol Metab. 71:1990;836-841.
4. Wimalawansa S Use of plasma 17β-estradiol as a guideline for parenteral administration of estrogen for the prevention and treatment of osteoporosis. Osteoporosis. 1990;1917-1922 Osteopress ApS, Copenhagen.
5. De Lignieres B Hormone replacement therapy compliance and individually adapted doses. Hormone Replacement Therapy: Standardized or Individually Adapted Doses? 1993;59-67 The Parthenon publishing group, London.
6. Wimalawansa S, Maclntyre I Can we determine the lowest dose of estradiol still active on bone? Recent Research in Gynecological Endocrinology. 1988;314-316 The Parthenon publishing group, Camforth.
7. Ylikorkala O Vascular effects of sex steroids: where do we stand now? The Modern Management of the Menopause. 1993;217-222 The Parthenon publishing group, London.
8. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994;suppl.2(62)(6):176S-79.
9. Williams JK, Shively CA, Clarkson TB Determinants of coronary artery reactivity in premenopausal female monkeys with diet-induced atherosclerosis. Circulation. 90:1994;983-987.
10. Steingold KA, Laufer L, Chetkowski RJ et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab. 61:1985;627-632.
11. Lobo RA Treatment of the postmenopausal women. Where are we today? Treatment of the Postmenopausal Women: Basic and Clinical Aspects. 1994;427-432 Raven press, New York.
12. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 117:1992;1-9.
13. De Lignieres B Hormone replacement therapy: clinical benefits and side-effects. Maturitas. suppl;23:1996;S31-36.
14. Tremolieres F, Pouilles JM, Louvet JP et al. Preventive effects on postmenopausal bone loss of percutaneous 17β-estradiol in early and late menopause. Osteoporosis. 1990;1910-1916 Osteopress ApS, Copenhagen.
15. Kronenberg F Hot flashes. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. 1994;97-117 New York, Raven press.
16. Tepper R, Goldberger S, Ilan C et al. Gynecol Obstet Invest. 38:1994;113-116.
17. Simon JA Estrogen pharmacokinetics: interindividual variations. Hormone Replacent Therapy: Standardized or Individually Adapted Doses? 1993;9-21 The Parthenon publishing group, London.
18. Moore J.W, Clark GMG, Bulbrook RD et al. Serum concentrations of total and non-protein-bound estradiol in patients with breast cancer and in normal controls. Int J Cancer. 29:1982;17-21.